JOP20190280A1 - مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية - Google Patents
مثبطات fgfr2 لعلاج سرطان الأوعية الصفراويةInfo
- Publication number
- JOP20190280A1 JOP20190280A1 JOP/2019/0280A JOP20190280A JOP20190280A1 JO P20190280 A1 JOP20190280 A1 JO P20190280A1 JO P20190280 A JOP20190280 A JO P20190280A JO P20190280 A1 JOP20190280 A1 JO P20190280A1
- Authority
- JO
- Jordan
- Prior art keywords
- treating
- patient
- treating cholangiocarcinoma
- fgfr2
- fgfr2 inhibitors
- Prior art date
Links
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 title abstract 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 title abstract 3
- 208000006990 cholangiocarcinoma Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 108091008794 FGF receptors Proteins 0.000 abstract 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174295 | 2017-06-02 | ||
| EP18171315 | 2018-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190280A1 true JOP20190280A1 (ar) | 2019-12-02 |
Family
ID=62555054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0280A JOP20190280A1 (ar) | 2017-06-02 | 2017-06-16 | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11707463B2 (enExample) |
| EP (1) | EP3634414A1 (enExample) |
| JP (2) | JP2020521794A (enExample) |
| KR (1) | KR20200010505A (enExample) |
| CN (1) | CN111050769A (enExample) |
| AU (1) | AU2018278271B2 (enExample) |
| BR (1) | BR112019025056A2 (enExample) |
| CA (1) | CA3064317A1 (enExample) |
| IL (1) | IL271058A (enExample) |
| JO (1) | JOP20190280A1 (enExample) |
| MA (1) | MA49248A (enExample) |
| MX (1) | MX2019014366A (enExample) |
| MY (1) | MY204203A (enExample) |
| PH (1) | PH12019502710A1 (enExample) |
| UA (1) | UA126478C2 (enExample) |
| WO (1) | WO2018220206A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| WO2020165181A1 (en) * | 2019-02-12 | 2020-08-20 | Janssen Pharmaceutica Nv | Cancer treatment |
| US20220054484A1 (en) * | 2019-03-29 | 2022-02-24 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| JP2022534742A (ja) * | 2019-05-28 | 2022-08-03 | キューイーディー セラピューティクス，インコーポレイテッド | 胆管癌を治療するための方法 |
| WO2021023178A1 (zh) * | 2019-08-05 | 2021-02-11 | 江苏恒瑞医药股份有限公司 | 一种吡咯并六元杂环化合物在制备治疗fgfr2基因变异的肿瘤的药物中的用途 |
| CN114945367A (zh) * | 2020-01-17 | 2022-08-26 | 贝达医药公司 | 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物 |
| CN111596058A (zh) * | 2020-05-18 | 2020-08-28 | 山东第一医科大学(山东省医学科学院) | 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法 |
| DE102021126650A1 (de) | 2021-10-14 | 2023-04-20 | Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts | Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff |
| KR20250117064A (ko) | 2024-01-26 | 2025-08-04 | 충북대학교 산학협력단 | 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1904480A2 (en) | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| JP2010525301A (ja) * | 2007-03-23 | 2010-07-22 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | 子宮内膜癌および前癌の診断、分類および治療の方法 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| LT3198033T (lt) | 2014-09-26 | 2022-05-10 | Janssen Pharmaceutica Nv | Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2017
- 2017-06-16 JO JOP/2019/0280A patent/JOP20190280A1/ar unknown
-
2018
- 2018-06-01 MY MYPI2019007030A patent/MY204203A/en unknown
- 2018-06-01 MA MA049248A patent/MA49248A/fr unknown
- 2018-06-01 MX MX2019014366A patent/MX2019014366A/es unknown
- 2018-06-01 US US16/616,067 patent/US11707463B2/en active Active
- 2018-06-01 BR BR112019025056-5A patent/BR112019025056A2/pt not_active Application Discontinuation
- 2018-06-01 EP EP18729631.4A patent/EP3634414A1/en active Pending
- 2018-06-01 WO PCT/EP2018/064523 patent/WO2018220206A1/en not_active Ceased
- 2018-06-01 AU AU2018278271A patent/AU2018278271B2/en not_active Ceased
- 2018-06-01 KR KR1020197038249A patent/KR20200010505A/ko not_active Ceased
- 2018-06-01 CN CN201880050198.0A patent/CN111050769A/zh active Pending
- 2018-06-01 UA UAA201912271A patent/UA126478C2/uk unknown
- 2018-06-01 CA CA3064317A patent/CA3064317A1/en active Pending
- 2018-06-01 JP JP2019566178A patent/JP2020521794A/ja not_active Withdrawn
-
2019
- 2019-11-29 PH PH12019502710A patent/PH12019502710A1/en unknown
- 2019-12-01 IL IL271058A patent/IL271058A/en unknown
-
2023
- 2023-05-10 JP JP2023077882A patent/JP2023113650A/ja active Pending
- 2023-06-26 US US18/341,023 patent/US12350266B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA49248A (fr) | 2020-04-15 |
| MX2019014366A (es) | 2020-07-27 |
| JP2020521794A (ja) | 2020-07-27 |
| CN111050769A (zh) | 2020-04-21 |
| CA3064317A1 (en) | 2018-12-06 |
| EP3634414A1 (en) | 2020-04-15 |
| WO2018220206A1 (en) | 2018-12-06 |
| AU2018278271B2 (en) | 2024-07-04 |
| US20240016801A1 (en) | 2024-01-18 |
| AU2018278271A1 (en) | 2019-12-05 |
| BR112019025056A2 (pt) | 2020-06-16 |
| KR20200010505A (ko) | 2020-01-30 |
| MY204203A (en) | 2024-08-15 |
| PH12019502710A1 (en) | 2020-06-08 |
| US12350266B2 (en) | 2025-07-08 |
| JP2023113650A (ja) | 2023-08-16 |
| IL271058A (en) | 2020-01-30 |
| US20200138809A1 (en) | 2020-05-07 |
| US11707463B2 (en) | 2023-07-25 |
| UA126478C2 (uk) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190280A1 (ar) | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية | |
| EA201790716A1 (ru) | Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr | |
| CL2018001110A1 (es) | Mutaciones de punto en cáncer resistente a inhibidor de trk y métodos relacionados con el mismo | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| MX394474B (es) | Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo. | |
| EA201592005A1 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| PH12017501967A1 (en) | Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof | |
| WO2015120094A3 (en) | Method of identifying tyrosine kinase receptor rearrangements in patients | |
| EP3686290A3 (en) | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer | |
| EA201992026A1 (ru) | Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5 | |
| BR112019005167A2 (pt) | método e kit para analisar uma amostra | |
| BR112019005172A2 (pt) | método e kit para analisar uma amostra | |
| AR100766A1 (es) | Sistema de expresión génica | |
| MX2019003569A (es) | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. | |
| EP4407047A3 (en) | Molecular detection of enterovirus and parechovirus | |
| FR3026194B1 (fr) | Forme d'onde radar, procede de detection radar utilisant une telle onde, et radar mettant en oeuvre le procede | |
| EA201992849A1 (ru) | Ингибиторы fgfr2 для лечения холангиокарциномы | |
| EA202190962A2 (ru) | Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом | |
| EA201690354A1 (ru) | Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом | |
| EA202190826A1 (ru) | Лечение холангиокарциномы | |
| UA95591U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95590U (uk) | Спосіб прогнозування зрощення перелому | |
| RU2015110486A (ru) | Способ оценки результатов воздействия микроорганизмов на пролиферацию клеток в макроорганизме | |
| BR112017010902A2 (pt) | método para identificar a presença ou ausência de um ácido nucleico alvo em uma amostra biológica. |